Request Sample Inquiry
Cancer Biologics Market

Cancer Biologics Market

Cancer Biologics Market - Global Industry Assessment & Forecast

img
Healthcare
Number Of Pages # Pages:

149

Base Year:

2023

Date

Jun - 2024

Format:

PDF XLS PPT

Report Code:

VMR-2506

Segments Covered
  • By Drug Class By Drug Class Monoclonal Antibodies, Cancer Growth Inhibitors, Vaccines, Recombinants Proteins , CAR-T Cells, Angiogenesis Inhibitors, Interleukins (IL), Interferons (IFN), Gene Therapy, Other Drug Classes
  • By Application By Application Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Gastric Cancer, Ovarian Cancer, Skin Cancer, Liver Cancer, Other Applications
  • By End Use By End Use Hospitals, Cancer Center, Academics & Research Institutes
  • By Region By Region North America , Europe , Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2023
Forecast YearsForecast Years: 2024 - 2032
Historical YearsHistorical Years: 2018 - 2022
Revenue 2023Revenue 2023: USD 109.1 Billion
Revenue 2032Revenue 2032: USD 197.1 Billion
Revenue CAGRRevenue CAGR (2024 - 2032): 6.79%
Fastest Growing Region Fastest Growing Region (2024 - 2032) Asia Pacific
Largest Region Largest Region (2023): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Cancer Biologics Market - Segment Analysis
    1. Overview
    2. Global Cancer Biologics Market, 2016 - 2028 (USD Million)
    3. Global Cancer Biologics Market - by Drug Class
      1. By Monoclonal Antibodies
      2. By Cancer Growth Inhibitors
      3. By Vaccines
      4. By Recombinants Proteins
      5. By CAR-T Cells
      6. By Angiogenesis Inhibitors
      7. By Interleukins (IL)
      8. By Interferons (IFN)
      9. By Gene Therapy
      10. By Other Drug Classes
    4. Global Cancer Biologics Market - by Application
      1. By Blood Cancer
      2. By Lung Cancer
      3. By Breast Cancer
      4. By Colorectal Cancer
      5. By Prostate Cancer
      6. By Gastric Cancer
      7. By Ovarian Cancer
      8. By Skin Cancer
      9. By Liver Cancer
      10. By Other Applications
    5. Global Cancer Biologics Market - by End Use
      1. By Hospitals
      2. By Cancer Center
      3. By Academics & Research Institutes
    6. Global Cancer Biologics Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    7. Market comparative analysis
  4. North America Cancer Biologics Market - Segment Analysis
    1. Overview
    2. North America Cancer Biologics Market, 2016 - 2028 (USD Million)
    3. North America Cancer Biologics Market, by Drug Class
      1. By Monoclonal Antibodies
      2. By Cancer Growth Inhibitors
      3. By Vaccines
      4. By Recombinants Proteins
      5. By CAR-T Cells
      6. By Angiogenesis Inhibitors
      7. By Interleukins (IL)
      8. By Interferons (IFN)
      9. By Gene Therapy
      10. By Other Drug Classes
    4. North America Cancer Biologics Market, by Application
      1. By Blood Cancer
      2. By Lung Cancer
      3. By Breast Cancer
      4. By Colorectal Cancer
      5. By Prostate Cancer
      6. By Gastric Cancer
      7. By Ovarian Cancer
      8. By Skin Cancer
      9. By Liver Cancer
      10. By Other Applications
    5. North America Cancer Biologics Market, by End Use
      1. By Hospitals
      2. By Cancer Center
      3. By Academics & Research Institutes
    6. North America Cancer Biologics Market, by Country
      1. U.S.
        1. U.S. Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. U.S. Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. U.S. Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      2. Canada
        1. Canada Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Canada Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Canada Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      3. Mexico
        1. Mexico Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Mexico Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Mexico Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
  5. Europe Cancer Biologics Market - Segment Analysis
    1. Overview
    2. Europe Cancer Biologics Market, 2016 - 2028 (USD Million)
    3. Europe Cancer Biologics Market, by Drug Class
      1. By Monoclonal Antibodies
      2. By Cancer Growth Inhibitors
      3. By Vaccines
      4. By Recombinants Proteins
      5. By CAR-T Cells
      6. By Angiogenesis Inhibitors
      7. By Interleukins (IL)
      8. By Interferons (IFN)
      9. By Gene Therapy
      10. By Other Drug Classes
    4. Europe Cancer Biologics Market, by Application
      1. By Blood Cancer
      2. By Lung Cancer
      3. By Breast Cancer
      4. By Colorectal Cancer
      5. By Prostate Cancer
      6. By Gastric Cancer
      7. By Ovarian Cancer
      8. By Skin Cancer
      9. By Liver Cancer
      10. By Other Applications
    5. Europe Cancer Biologics Market, by End Use
      1. By Hospitals
      2. By Cancer Center
      3. By Academics & Research Institutes
    6. Europe Cancer Biologics Market, by Country
      1. Germany
        1. Germany Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Germany Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Germany Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      2. UK
        1. UK Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. UK Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. UK Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      3. France
        1. France Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. France Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. France Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      4. Spain
        1. Spain Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Spain Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Spain Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      5. Italy
        1. Italy Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Italy Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Italy Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      6. BENELUX
        1. BENELUX Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. BENELUX Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. BENELUX Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      7. Rest of Europe
        1. Rest Of Europe Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Rest Of Europe Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Rest Of Europe Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
  6. Asia Pacific Cancer Biologics Market - Segment Analysis
    1. Overview
    2. Asia Pacific Cancer Biologics Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Cancer Biologics Market, by Drug Class
      1. By Monoclonal Antibodies
      2. By Cancer Growth Inhibitors
      3. By Vaccines
      4. By Recombinants Proteins
      5. By CAR-T Cells
      6. By Angiogenesis Inhibitors
      7. By Interleukins (IL)
      8. By Interferons (IFN)
      9. By Gene Therapy
      10. By Other Drug Classes
    4. Asia Pacific Cancer Biologics Market, by Application
      1. By Blood Cancer
      2. By Lung Cancer
      3. By Breast Cancer
      4. By Colorectal Cancer
      5. By Prostate Cancer
      6. By Gastric Cancer
      7. By Ovarian Cancer
      8. By Skin Cancer
      9. By Liver Cancer
      10. By Other Applications
    5. Asia Pacific Cancer Biologics Market, by End Use
      1. By Hospitals
      2. By Cancer Center
      3. By Academics & Research Institutes
    6. Asia Pacific Cancer Biologics Market, by Country
      1. China
        1. China Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. China Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. China Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      2. Japan
        1. Japan Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Japan Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Japan Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      3. India
        1. India Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. India Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. India Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      4. South Korea
        1. South Korea Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. South Korea Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. South Korea Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      5. South East Asia
        1. South East Asia Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. South East Asia Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. South East Asia Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Rest of Asia Pacific Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Rest of Asia Pacific Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
  7. Latin America Cancer Biologics Market - Segment Analysis
    1. Overview
    2. Latin America Cancer Biologics Market, 2016 - 2028 (USD Million)
    3. Latin America Cancer Biologics Market, by Drug Class
      1. By Monoclonal Antibodies
      2. By Cancer Growth Inhibitors
      3. By Vaccines
      4. By Recombinants Proteins
      5. By CAR-T Cells
      6. By Angiogenesis Inhibitors
      7. By Interleukins (IL)
      8. By Interferons (IFN)
      9. By Gene Therapy
      10. By Other Drug Classes
    4. Latin America Cancer Biologics Market, by Application
      1. By Blood Cancer
      2. By Lung Cancer
      3. By Breast Cancer
      4. By Colorectal Cancer
      5. By Prostate Cancer
      6. By Gastric Cancer
      7. By Ovarian Cancer
      8. By Skin Cancer
      9. By Liver Cancer
      10. By Other Applications
    5. Latin America Cancer Biologics Market, by End Use
      1. By Hospitals
      2. By Cancer Center
      3. By Academics & Research Institutes
    6. Latin America Cancer Biologics Market, by Country
      1. Brazil
        1. Brazil Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Brazil Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Brazil Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      2. Argentina
        1. Argentina Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Argentina Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Argentina Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      3. Rest of Latin America
        1. Rest of Latin America Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Rest of Latin America Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Rest of Latin America Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
  8. Middle East & Africa Cancer Biologics Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Cancer Biologics Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Cancer Biologics Market, by Drug Class
      1. By Monoclonal Antibodies
      2. By Cancer Growth Inhibitors
      3. By Vaccines
      4. By Recombinants Proteins
      5. By CAR-T Cells
      6. By Angiogenesis Inhibitors
      7. By Interleukins (IL)
      8. By Interferons (IFN)
      9. By Gene Therapy
      10. By Other Drug Classes
    4. Middle East & Africa Cancer Biologics Market, by Application
      1. By Blood Cancer
      2. By Lung Cancer
      3. By Breast Cancer
      4. By Colorectal Cancer
      5. By Prostate Cancer
      6. By Gastric Cancer
      7. By Ovarian Cancer
      8. By Skin Cancer
      9. By Liver Cancer
      10. By Other Applications
    5. Middle East & Africa Cancer Biologics Market, by End Use
      1. By Hospitals
      2. By Cancer Center
      3. By Academics & Research Institutes
    6. Middle East & Africa Cancer Biologics Market, by Country
      1. GCC Countries
        1. GCC Countries Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. GCC Countries Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. GCC Countries Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      2. South Africa
        1. South Africa Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. South Africa Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. South Africa Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Cancer Biologics Market, By Drug Class
          1. By Monoclonal Antibodies
          2. By Cancer Growth Inhibitors
          3. By Vaccines
          4. By Recombinants Proteins
          5. By CAR-T Cells
          6. By Angiogenesis Inhibitors
          7. By Interleukins (IL)
          8. By Interferons (IFN)
          9. By Gene Therapy
          10. By Other Drug Classes
        2. Rest of Middle East & Africa Cancer Biologics Market, By Application
          1. By Blood Cancer
          2. By Lung Cancer
          3. By Breast Cancer
          4. By Colorectal Cancer
          5. By Prostate Cancer
          6. By Gastric Cancer
          7. By Ovarian Cancer
          8. By Skin Cancer
          9. By Liver Cancer
          10. By Other Applications
        3. Rest of Middle East & Africa Cancer Biologics Market, By End Use
          1. By Hospitals
          2. By Cancer Center
          3. By Academics & Research Institutes
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Abbott Laboratories (U.S.)
    2. Angel Pharmaceuticals (China)
    3. Amgen Inc. (U.S.)
    4. AstraZeneca (UK)
    5. BioNTech (Germany)
    6. Bristol-Mayer Squibb Company (U.S.)
    7. Dr. Reddy's Laboratories (India)
    8. Duality Biologics (China)
    9. Eli Lilly and Company (U.S.)
    10. F. Hoffmann-La Roche Ltd. (Switzerland)
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 26-Jun-2024
Breakthroughs in Cancer Biologics: Promising Trials, New Data, and Expanded Access
FAQ
Frequently Asked Question

  • The global Cancer Biologics valued at USD 109.1 Billion in 2023 and is expected to reach USD 197.1 Billion in 2032 growing at a CAGR of 6.79%.

  • The prominent players in the market are Abbott Laboratories (U.S.), Angel Pharmaceuticals (China), Amgen Inc. (U.S.), AstraZeneca (UK), BioNTech (Germany), Bristol-Mayer Squibb Company (U.S.), Dr. Reddy's Laboratories (India), Duality Biologics (China), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland).

  • The market is project to grow at a CAGR of 6.79% between 2024 and 2032.

  • The driving factors of the Cancer Biologics include

  • North America was the leading regional segment of the Cancer Biologics in 2023.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy